OSLO, Norway, Nov. 11, 2019 /PRNewswire/ -- Targovax ASA
(OSE: TRVX), announces that clinical data from its combination
trial with ONCOS-102 and Keytruda in anti-PD1 refractory melanoma
was presented at the Society for Immunotherapy of Cancer (SITC)
Annual Meeting
Dr. Shoushtari, MD, Medical Oncologist, Memorial Sloan
Kettering, presented results from part 1 of Targovax's phase I
trial in anti-PD1 refractory melanoma combining ONCOS-102 with
Keytruda. Headline data were released in July, showing that three
out of nine patients had significant reduction of tumor burden (33%
overall response rate, ORR), including one patient with a complete
response, which is rarely seen in this late-stage patient
population Please see the full presentation here: SITC
presentation
Øystein Soug, CEO of Targovax, commented: "Although the
number of patients is small, 33% ORR is very encouraging and
confirms our hypothesis that ONCOS-102 can immune activate PD-1
refractory tumors to respond to re-challenge with Keytruda. We are
very excited that these data are being recognized with an oral
presentation at the SITC Annual Meeting."
Part 2 of the trial is currently enrolling patients, where an
extended ONCOS-102 dosing regimen is being assessed.
An extended presentation will be given by Dr. Shoushtari at an
investor event in NYC later this week:
SOLEBURY TROUT KOL DAY
Date:
|
15 November
2019
|
Time and
place
|
2 pm ET; NYC,
US
|
Presenter:
|
Dr. Alexander
Shoushtari, Principal Investigator, Memorial Sloan Kettering Cancer
Center, NYC
|
Webcast:
|
https://services.choruscall.com/links/trvx191115.html
|
For more information about the Solebury Trout KOL day or to
RSVP, institutional investors and sell-side analysts may contact
access@troutgroup.com.
KOL biography:
Alexander N. Shoushtari, MD,
Medical Oncologist, Memorial Sloan Kettering
Dr. Shoushtari is a renowned expert in melanoma, with a research
focus on uveal and mucosal melanomas. He has been part of several
immunotherapy trials at MSKCC and is the Principal Investigator on
the ONCOS-102 phase I trial in CPI refractory advanced melanoma.
Dr. Shoushtari is a member of the research team of Dr. Jedd Wolchok, MD, PhD, Chief, Melanoma and
Immunotherapeutics Service at the Memorial Sloan Kettering Cancer
Center.
For further information, please contact:
Renate Birkeli
Investor Relations
Phone: +47-922-61-624
Email: renate.birkeli@targovax.com
Media and IR enquires:
Andreas Tinglum - Corporate
Communications (Norway)
Phone: +47-9300-1773
Email: andreas.tinglum@corpcom.no
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/targovax/r/presentation-of-oncos-102-melanoma-data-at-sitc-annual-meeting,c2958264
The following files are available for download:
https://mb.cision.com/Public/17093/2958264/920422e203543ab4.pdf
|
SITC
presentation
|